Concepedia

Amber Gordon

AG

Statistics

Publications

11

Citations

3K

H-Index

11

Active since

2010

Affiliations

The Ohio State University(Current)

The Ohio State University Wexner Medical Center

Amber Gordon is an author at The Ohio State University specializing in oncology, chronic lymphocytic leukemia therapy, and molecular oncology.

Publications per year

2010–2020

11

Publications

11

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765

Sarah E. M. Herman, Amber Gordon, Erin Hertlein et al. · Blood · 2011 · 791 citations · Full text

, , +15

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

Kami J. Maddocks, Amy S. Ruppert, Gerard Lozanski et al. · JAMA Oncology · 2015 · 576 citations · Full text

, , +16

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

Sarah E. M. Herman, Amber Gordon, Amy J. Wagner et al. · Blood · 2010 · 541 citations · Full text

, , +16

<i>BTK</i><sup>C481S</sup>-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia

Jennifer A. Woyach, Amy S. Ruppert, Daphne Guinn et al. · Journal of Clinical Oncology · 2017 · 471 citations

, , +16

Ibrutinib treatment improves T cell number and function in CLL patients

Meixiao Long, Kyle A. Beckwith, Priscilla Do et al. · Journal of Clinical Investigation · 2017 · 377 citations · Full text

, , +17

1–5 of 11